Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome

Phase 3

Conditions: Idiopathic Nephrotic Syndrome
Minimal Change Disease
Focal Segmental Glomerulosclerosis

Interventions: Drug: Rituximab
Drug: Prednisone

First Posted Date: 2017-10-02

Last Posted Date: 2018-08-27

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 40

Registration Number: NCT03298698

Locations: 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

Phase 1

Completed

Conditions: Diffuse B-Cell Lymphoma

Interventions: Drug: Avadomide (CC-122)
Drug: Rituximab
Drug: Cyclophosphamide 750mg/m2 by IV infusion
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2017-09-14

Last Posted Date: 2021-04-29

Lead Sponsor: Celgene

Target Recruit Count: 35

Registration Number: NCT03283202

Locations: 🇪🇸
Hospital Universitario Virgen Del Rocio, Sevilla, Spain
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States

and more 12 locations

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Adenocarcinoma
Stage IIIA Prostate Cancer AJCC v8
Stage IIB Prostate Cancer AJCC v8
Stage IIIC Prostate Cancer AJCC v8
Stage IIC Prostate Cancer AJCC v8

Interventions: Drug: Apalutamide
Drug: Abiraterone Acetate
Biological: Gonadotropin-releasing Hormone Analog
Procedure: Radical Prostatectomy
Drug: Prednisone

First Posted Date: 2017-09-12

Last Posted Date: 2022-08-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 86

Registration Number: NCT03279250

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Phase 3

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Polatuzumab Vedotin
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine Placebo
Drug: Polatuzumab vedotin Placebo

First Posted Date: 2017-09-07

Last Posted Date: 2025-01-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1000

Registration Number: NCT03274492

Locations: 🇷🇺
Leningrad Regional Clinical Hospital, St Petersburg, Sankt Petersburg, Russian Federation
🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 213 locations

Short Term Effect of Glucocorticoids on Brown Adipose Tissue Thermogenesis in Humans

Phase 4

Completed

Conditions: Brown Adipose Tissue

Interventions: Drug: Placebo
Drug: Prednisone

First Posted Date: 2017-09-01

Last Posted Date: 2019-06-05

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 16

Registration Number: NCT03269747

Locations: 🇨🇭
University Hospital Basel, Department of Endocrinology, Basel, BS, Switzerland

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2

Active, not recruiting

Conditions: Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Recurrent Follicular Lymphoma
Grade 1 Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions: Procedure: Biopsy
Drug: Bendamustine Hydrochloride
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Drug: Lenalidomide
Drug: Cyclophosphamide
Biological: Obinutuzumab
Drug: Doxorubicin Hydrochloride
Procedure: Positron Emission Tomography
Drug: Umbralisib
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2017-09-01

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT03269669

Locations: 🇺🇸
Longmont United Hospital, Longmont, Colorado, United States
🇺🇸
Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States
🇺🇸
Banner McKee Medical Center, Loveland, Colorado, United States

and more 430 locations